StockData
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO) income statement

ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.85+0.04 (+5.13%)

Close on Nov 18, 2026Market cap $109.79MP/E –Yield –

Organogenesis Holdings Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-7.8%
Net margin
-18.4%
Return on equity, FY2025
13.2%

Financial strength

Current ratio
3.52
Debt to equity
–
Debt to assets
–
Cash to current liabilities
80.9%

Valuation

P/E ratio
–
Price to sales
0.24
Price to book
0.74
Dividend yield
–

See a number that looks wrong?